Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celldex Therapeutics Inc's Rindopepimut demonstrates promising clinical activity in patients with EGFRvIII-positive recurrent Glioblastoma


Sunday, 24 Nov 2013 01:25pm EST 

Celldex Therapeutics Inc:Reports interim data from its ongoing, exploratory Phase 2 ReACT study of rindopepimut in recurrent glioblastoma.Says Rindopepimut is an immunotherapeutic vaccine that targets the tumor specific oncogene EGFRvIII(v3).Says patients with EGFRvIII-positive glioblastoma typically have a worse prognosis than the overall glioblastoma population, including poor long term survival.Says the ReACT results demonstrate promising signs of clinical activity in advanced patient populations, including patients both na├»ve and refractory to bevacizumab (Avastin).Says an update on long-term survival for the three completed Phase 2 frontline studies in EGFRvIII-positive glioblastoma was also presented and results continue to exceed outcomes seen in contemporary controls. 

Company Quote

15.28
0.77 +5.31%
11:04am EDT